[1][2][3] While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

[1] Additional discovery partnerships included: Bayer (1999), Roche (2000), Centocor (now Janssen Biotech, 2000), Schering AG (2001) and Pfizer (2003).

[9][10] In April 2018, following a US initial public offering in which the company raised $239 million, American depositary shares of MorphoSys began trading on the Nasdaq stock exchange, also under the symbol "MOR.

In December 2019, based on positive clinical trial results, the company submitted a Biologics License Application (BLA) to the FDA for tafasitamab in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

[14] In January 2020, MorphoSys and Incyte Corporation signed a collaboration and license agreement for the global development and commercialization of tafasitamab.

[16] In March 2020, MorphoSys announced that the FDA had accepted the Biologics License Application (BLA) for filing and granted priority review for tafasitamab, setting a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2020.

[17] On July 31, 2020, Monjuvi (tafasitamab-cxix) was approved by the U.S. FDA in combination with lenalidomide for the medical treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

According to the press release, this step is justified by challenges in the pharmaceutical market, which are forcing the company to optimize its cost structure and to focus all resources more on oncology products in the mid to late stage of development.

MorphoSys’ OkapY technology is a new proprietary “2+1” bispecific antibody format with the hysicochemical properties to simplify the development and large-scale production of such molecules.